Advances in Genetic Engineering & BiotechnologyISSN: 2324-9021

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Omics-Based CHO Cell Engineering Entrance into Post-Genomic Era

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations